Albany, NY -- (SBWIRE) -- 05/30/2014 -- Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly impairs the patient’s physical and mental wellbeing. The primary cause of psoriasis is unknown, as are the mechanisms that lead to immune cells directing inflammatory responses towards the skin. Within the lucrative autoimmune market, the psoriasis market has grown considerably due to the repositioning of all three marketed Tumor Necrosis Factor (TNF) inhibitors: Humira (adalimumab) and Enbrel (etanercept) which were originally approved for rheumatoid arthritis, and also Remicade (infliximab), the first biologic to be approved for Crohn’s disease, an autoimmune disease which largely affects the gastrointestinal system.
View Full Report With Complete TOC or Request Sample of This Report at http://www.researchmoz.us/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-report.html
Related Reports -
Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug’s performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape.
View Full Report With Complete TOC at http://www.researchmoz.us/frontier-pharma-systemic-lupus-erythematosus-identifying-and-commercializing-first-in-class-innovation-report.html
Frontier Pharma - Rheumatoid Arthritis: Identifying and Commercializing First-in-Class Innovation
“Frontier Pharma: Rheumatoid Arthritis Identifying and Commercializing First-in-Class Innovation”. This highly competitive market is saturated with multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet more of these treatments are expected to enter the market over the next few years. Despite this, the current developmental pipeline is highly innovative beyond these me-too products and incremental innovations and promises a number of first-in-class products across all stages. These new developments are driven by improvements in the understanding of signaling pathways and underlying disease mechanisms of Rheumatoid Arthritis (RA). These highly innovative products are expected to increase the diversity of available products, in terms of mechanism of action over the coming decade and are likely to have a significant impact on the dynamics of the clinical and commercial landscape.
View Full Report With Complete TOC at http://www.researchmoz.us/frontier-pharma-rheumatoid-arthritis-identifying-and-commercializing-first-in-class-innovation-report.html
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Browse Blog - http://pramoddige91.wordpress.com/